{
    "key_points": [
        "The FDA expands the use of booster doses for COVID-19 vaccines in eligible populations.",
        "Moderna's booster is authorized for people 65+ and those 18-64 at high risk or with frequent exposure to SARS-CoV-2, 6 months after the primary series.",
        "Janssen's booster is authorized for individuals 18 and older, 2 months after the initial dose.",
        "Pfizer-BioNTech's booster clarified for 18-64 year-olds with frequent exposure, 6 months after the primary series.",
        "FDA approves 'mix and match' booster approach for all available COVID-19 vaccines.",
        "Safety and immunity response data from clinical trials support the booster dose authorizations.",
        "Side effects for booster doses are similar to those experienced after the primary doses.",
        "FDA and CDC identify increased risks of myocarditis, pericarditis, and other conditions linked to COVID-19 vaccines but affirm overall safety.",
        "Eligibility and dosing interval for 'mix and match' boosters align with those for vaccines used in primary vaccination.",
        "Health care providers are encouraged to follow CDC recommendations on booster administrations."
    ],
    "spokespersons": [
        "Janet Woodcock, M.D. (Acting FDA Commissioner)",
        "Peter Marks, M.D., Ph.D. (Director, FDAâ€™s Center for Biologics Evaluation and Research)"
    ],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}